Article

Macusight's lead product has positive phase 1 results

Union City, CA-MacuSight's lead product candidate, sirolimus, for patients with chronic, clinically significant diabetic macular edemahas shown positive initial results in its phase 1 study.

Union City, CA-MacuSight's lead product candidate, sirolimus, for patients with chronic, clinically significant diabetic macular edemahas shown positive initial results in its phase 1 study.

These findings were presented at the 40th annual meeting of the Retina Society by Mark Blumenkranz, MD, chairmen of MacuSight's scientific advisory board and professor and chairman of the department of ophthalmology, Stanford University School of Medicine.

The study was randomized, open-label and investigators analyzed the safety, tolerability, and biological activity of sirolimus when delivered by either subconjunctival or intravitreal injection.

Subconjunctival injections, which are less invasive and more convenient, were used instead of the intravitreal injections, which sometimes caused patient discomfort and a risk of serious infection in some patients.

Patients who received the subconjunctival injection had mean improvements in visual acuity of 8.5 and 7.4 letters over baseline, using the standard ETDRS eye chart. Foveal thickness also decreased.

There was no sign of increased IOP or inflammatory response, and MacuSight intends to complete its collection and analysis of all data from this trial and present final findings next year.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.